Lucid Diagnostics Inc. (LUCD) - Dilution Analysis

10-Q filing | 164.9M shares outstanding

10-K filing | 131.1M shares outstanding

8-K filing: The Company closed on the sale of 28,750,000 shares of its common stock at a price of $1.00 per share in its previously announced underwritten offering, resulting in net proceeds of approximately $26.9 million. ($28.75M proceeds)

8-K filing: Lucid Diagnostics Inc. entered into an underwriting agreement for a public offering of 25,000,000 shares of common stock at $1.00 per share, with an option for the underwriters to purchase an additional 3,750,000 shares. ($28.75M proceeds)

10-Q filing | 99.0M shares outstanding

S-3 filing: This S-3 filing relates to the potential offer and sale from time to time of up to 36,975,000 shares of the company's common stock by selling stockholders.

10-Q filing | 91.0M shares outstanding

8-K filing: The Company closed on the sale of 14,375,000 shares of common stock at a price of $1.20 per share, resulting in net proceeds of approximately $16.1 million, which will be used for working capital and general corporate purposes.

8-K filing: Lucid Diagnostics Inc. entered into an underwriting agreement to sell 12,500,000 shares of common stock at $1.20 per share, with an option for underwriters to purchase an additional 1,875,000 shares, resulting in estimated gross proceeds of $15.0 million, before deducting the underwriting discount and offering expenses. ($17.25M proceeds)

10-K filing | 67.0M shares outstanding

8-K filing: The Company closed on the sale of 13,939,331 shares of its common stock at a price of $1.10 per share, with net proceeds estimated at $14.5 million, to be used for working capital and general corporate purposes. ($15.33M proceeds)

8-K filing: Lucid Diagnostics Inc. entered into a placement agency agreement with Canaccord Genuity LLC for a proposed offering of common stock, and subscription agreements with investors to sell 13,939,331 shares at $1.10 per share, resulting in gross proceeds of approximately $15.3 million. ($15.3M proceeds)

8-K filing: Lucid Diagnostics Inc. terminated its ATM Prospectus Supplement, under which it had sold 230,068 shares of common stock for an aggregate purchase price of $292,790. ($0.29M proceeds)

10-Q filing | 50.4M shares outstanding

10-Q filing | 48.2M shares outstanding

S-3/A filing: This prospectus relates to the potential offer and sale from time to time of 72,355,496 shares of our common stock by the selling stockholders.

S-3 filing: This S-3 filing relates to the potential offer and sale from time to time of 72,355,496 shares of common stock by selling stockholders.

10-Q filing | 45.0M shares outstanding

8-K filing: Lucid Diagnostics Inc. sold approximately 11,634 shares of Series B-1 Convertible Preferred Stock to accredited investors at a purchase price of $1,000 per share, resulting in gross proceeds of approximately $11.6 million. ($11.6M proceeds)

10-K filing | 48.2M shares outstanding

8-K filing: The Company entered into subscription agreements and exchange agreements with certain accredited investors for the sale and exchange of Series B Preferred Stock, resulting in aggregate gross proceeds to the Company of $18.16 million. ($18.17M proceeds)

8-K filing: Lucid Diagnostics Inc. issued 3,331,771 shares of its common stock to PAVmed Inc. on January 26, 2024, in exchange for $4,675,256 of fees and reimbursements accrued under the MSA and the PBERA. ($4.68M proceeds)

10-Q filing | 41.9M shares outstanding

8-K filing: Lucid Diagnostics Inc. sold 5,000 shares of Series A-1 Convertible Preferred Stock at $1,000 per share for $5.0 million in gross proceeds on October 18, 2023. ($5.0M proceeds)

10-Q filing | 41.8M shares outstanding

S-3 filing: This prospectus relates to the potential offer and sale from time to time of 25,688,308 shares of common stock by the selling stockholder as set forth in the filing.

10-Q filing | 41.0M shares outstanding

10-K filing | 43.4M shares outstanding

8-K filing: Lucid Diagnostics Inc. sold 13,625 shares of Series A Convertible Preferred Stock at $1,000 per share on March 7, 2023, for gross proceeds of $13.625 million. ($13.63M proceeds)

8-K filing: Lucid Diagnostics Inc. issued shares of common stock to PAVmed Inc. in three separate transactions: 750,818 shares for management services fees, 1,479,326 shares for payroll and benefit expense reimbursements, and 1,145,086 shares related to the CapNostics Assignment Agreement. ($6.47M proceeds)

S-3 filing: Lucid Diagnostics Inc. may offer and sell from time to time shares of common stock, shares of preferred stock, debt securities, warrants and/or units comprised of one or more of the other classes of securities offered hereby, at an aggregate initial offering price not to exceed $125,000,000.

10-Q filing | 36.4M shares outstanding

10-Q filing | 35.8M shares outstanding

S-1/A filing: This prospectus relates to the potential offer and sale from time to time by CF Principal Investments LLC of up to 15,000,000 shares of our common stock, that may be issued by us to the Holder pursuant to a common stock purchase agreement.

S-1 filing: This S-1 filing relates to the potential offer and sale from time to time by CF Principal Investments LLC of up to 15,000,000 shares of common stock, with the company potentially receiving up to $50.0 million in aggregate gross proceeds.

10-Q filing | 35.1M shares outstanding

10-K filing | 37.4M shares outstanding

10-Q filing | 36.8M shares outstanding

8-K filing: Lucid Diagnostics Inc. consummated its initial public offering of 5,000,000 shares of common stock at $14.00 per share, generating gross proceeds of $70,000,000. ($70.0M proceeds)

S-1/A filing: This is an S-1/A filing related to an offering of common stock, as detailed in the included exhibits and agreements with underwriters. The document includes representations and warranties by the company to the underwriters.

S-1/A filing: This is an initial public offering of up to 5,000,000 shares of the common stock of Lucid Diagnostics Inc. The public offering price per share is anticipated to be between $14.00 and $16.00.

S-1/A filing: The company issued a $22.4 million convertible promissory note to PAVmed in exchange for the cancellation of $22.4 million payable by the company.

S-1 filing: This is an initial public offering of up to [●] shares of the common stock of Lucid Diagnostics Inc.